SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25 – 30, 2025 in Chicago, IL. These include: (1) a poster presentation of Abdera’s ongoing Phase 1 clinical trial for ABD-147, a DLL3-targeting radiopharmaceutical, and (2) preclinical data on ABD-320, a 5T4-targeting radiopharmaceutical and Abdera’s second development program.
“We are pleased with the progress we’re making at Abdera and are excited to share our developments at AACR this year,” said Lori Lyons-Williams, president and chief executive officer. “Our first-in-human Phase 1 study for ABD-147 is enrolling and dosing patients. We are also unveiling compelling preclinical data for ABD-320, the first radiopharmaceutical therapy in development targeting 5T4. This widely prevalent target is associated with poor outcomes across multiple cancer types and we look forward to advancing ABD-320 into clinical development in the first half of 2026.”
Details of the presentations are as follows:
Title: A phase 1a/b, open-label, dose-escalation study of 225Ac-ABD147 for locally advanced or metastatic small cell lung cancer and large cell neuroendocrine carcinoma of the lung following platinum-based chemotherapy
Abstract Number: CT107 / 2
Session: PO.CTP01.01 – Phase I Clinical Trials in Progress 1
Date/Time: April 28, 2025 / 2:00 PM – 5:00 PM
Location: Section 51
